Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2026Targeted OncologyOpen Access

Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast

View Full Paper
Ask AI
Bookmark
Share

Authors

DNDanny Nguyen

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates noninferior efficacy in advanced NSCLC with subcutaneous amivantamab, suggesting improved patient experience.

Key Points

  • This research investigates the efficacy, safety, and administration of subcutaneous amivantamab versus intravenous delivery in advanced NSCLC.
  • Investigated noninferiority of pharmacokinetics and safety of SC versus IV amivantamab in advanced NSCLC patients.
  • Analyzed efficacy endpoints including objective response rate and progression-free survival.
  • Monitored infusion-related reactions and treatment administration times.
  • The objective response rate was 30% for SC amivantamab and 33% for IV amivantamab.
  • SC amivantamab administration resulted in 13% of patients reporting infusion-related reactions compared to 66% for IV.
  • Administration time for SC was less than 5 minutes compared to approximately 5 hours for IV.

Cite This Study

Danny Nguyen (2026) studied this question.

synapsesocial.com/papers/6a76da64f12abadc79814958https://doi.org/10.1007/s11523-026-01248-7
View Full Paper
Ask AI
Bookmark
Share